Filters
Results 1 - 1 of 1
Results 1 - 1 of 1.
Search took: 0.028 seconds
AbstractAbstract
[en] Prostatic carcinoma is currently the most common male cancer in France, accounting for almost a quarter of new cancers occurring each year. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein over-expressed in 95% of prostate cancers, making it a prime target. Numerous molecules targeting PSMA have been developed and the most studied ligand at present is gallium 68-labelled PSMA-11 (68Ga-PSMA-11). The use of this radiopharmaceutical in positron emission tomography (PET) imaging allows for better detection of prostatic carcinoma metastases as well as prostatic carcinoma in biochemical recurrence. The objective of this work is to undertake the production of this radiopharmaceutical drug by the radiopharmacy of the Angers university hospital. Several synthesis tests of 68Ga-PSMA-11 have been carried out, as well as the required quality controls on the final product. These tests are the first step in setting up this new examination in the Nuclear Medicine department of the Angers university hospital. (author)
[fr]
Le carcinome prostatique est aujourd'hui en France le cancer masculin le plus frequent, representant pres d'un quart des nouveaux cancers incidents annuels. L'antigene membranaire de la prostate (PSMA) est une glycoproteine transmembranaire surexprimee dans 95% des cancers prostatiques, il s'agit donc d'une cible de choix. De nombreuses molecules ciblant le PSMA ont ete developpes et le ligand le plus etudie actuellement est le PSMA-11 marque au gallium 68 (68Ga-PSMA-11). L'utilisation de ce medicament radiopharmaceutique en imagerie par tomographie par emission de positon (TEP) permet une meilleure detection des metastases du carcinome prostatique ainsi que du carcinome prostatique en recidive biochimique. L'objectif de ce travail est d'entreprendre la production de ce medicament radiopharmaceutique par la radiopharmacie du CHU d'Angers. Plusieurs essais de synthese du 68Ga-PSMA-11 ont ete realises, ainsi que les controles qualite requis sur le produit final. Ces essais constituent la premiere etape pour la mise en place de ce nouvel examen dans le service de Medecine Nucleaire du CHU d'Angers. (auteur)Original Title
68Ga-PSMA-11, un nouveau traceur TEP pour l'imagerie du carcinome prostatique: essais de production au sein de la radiopharmacie du CHU d'Angers
Primary Subject
Secondary Subject
Source
15 Oct 2020; 105 p; 185 refs.; Available from the INIS Liaison Officer for France, see the INIS website for current contact and E-mail addresses; These d'etat de Docteur en Pharmacie, Memoire du diplome d'etudes specialisees, Specialite: pharmacie hospitaliere
Record Type
Miscellaneous
Literature Type
Thesis/Dissertation
Report Number
Country of publication
ANTIGENS, BETA DECAY RADIOISOTOPES, BETA-PLUS DECAY RADIOISOTOPES, BODY, COMPLEXES, COMPUTERIZED TOMOGRAPHY, CONTROL, DAYS LIVING RADIOISOTOPES, DIAGNOSTIC TECHNIQUES, DISEASES, DRUGS, ELECTRON CAPTURE RADIOISOTOPES, EMISSION COMPUTED TOMOGRAPHY, EVEN-EVEN NUCLEI, GALLIUM ISOTOPES, GERMANIUM ISOTOPES, GLANDS, HAZARDOUS MATERIALS, HOURS LIVING RADIOISOTOPES, INTERMEDIATE MASS NUCLEI, ISOTOPES, LABELLED COMPOUNDS, MALE GENITALS, MATERIALS, NEOPLASMS, NUCLEI, ODD-ODD NUCLEI, ORGANS, RADIOACTIVE MATERIALS, RADIOISOTOPES, SYNTHESIS, TOMOGRAPHY, TOXIC MATERIALS, TOXINS
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue